[Portfolio Weekly Report 2026-07-03]
Health Score: 4/10
Total Floating P&L: Unknown (6 positions)
Sector Distribution: Tech 64%, Industrials 32%, Materials 2%, Healthcare 1%
⚠️ Concentration Risk: Tech sector at 64%, exceeding single-sector cap of 50%
Key Risks:
- Tech sector concentration at 64%, well above the 50% safety line; a chip/telecom sector pullback would severely impact the portfolio
- QCOM (28 shares / $5,928) and LMT (12 shares / $6,262) together account for ~63% of the portfolio, extremely high single-stock risk
- ASTS (91 shares / $6,355) is a high-risk growth stock, ~33% of cost basis, highly volatile and not yet profitable
- EDIT (52 shares / $168.48) only 1%, but news shows continued price decline; unclear rationale for holding
- No defensive assets like bonds or broad-based ETFs; portfolio lacks buffer
Suggested Actions:
- Reduce tech sector (QCOM/ASTS) to below 50%, free up capital for healthcare/materials (target adding to EDIT or DD)
- Add 10%+ defensive positions (e.g., S&P 500 ETF or short-term Treasury ETF) to lower systemic risk
- Clarify the logic for EDIT—if purely speculative, consider cutting losses; if long-term hold, increase position to at least 5% in the gene-editing space
- Review sector concentration quarterly; prioritize non-tech stocks for new additions
Portfolio health is low (4/10): Core issue is excessive tech concentration (64%), with LMT, QCOM, and ASTS making up over 95% of positions. ASTS and EDIT are both high-risk, unprofitable names. The portfolio lacks defensive assets and has weak risk resilience. Recommend reducing tech concentration, adding defensive positions, and clarifying the strategy for the losing position (EDIT). The CSI 300 approach of balanced allocation can serve as a reference—the key is to let different sectors truly hedge each other.